The Real-World Control-IQ Glycemic Control and Quality of Life Study in Type 1 Diabetes in France

Inclusion Criteria:

• Clinician-confirmed type 1 diabetes and for whom the site has initiated the t:slimX2 insulin pump with Control-IQ technology (Control-IQ System) with a Dexcom G6 orG7 CGM sensor.

• Age ≥ 6 years at enrollment.

• Using an insulin approved for use in the pump.

• Ability for patient or parent/guardian to respond to alerts and alarms, and toprovide basic diabetes self-management.

• Reside full-time in mainland France.

• Have an email address and mobile phone number

• Participant or participant's parent/guardian has read and understood the informationnotice and has agreed to participate in the study. This includes agreeing to :

1. use Control-IQ technology, and to continue use for at least 12 consecutivemonths after study enrollment.

2. the reuse of their clinical data including HbA1c results, obtained at most 4months prior to enrollment, and as available according to the standard of careduring the next 12 months.

3. complete questionnaires per the study protocol.

Exclusion Criteria:

• A medical or other condition, or medications being taken that, in the investigator'sjudgement would be a safety concern for participation in the study.

• Patients considered vulnerable under French law.